First case series on the use of imiquimod for morphoea

British Journal of Dermatology

Volumn 153, Issue 4, 2005, Pages 815-820

  Dytoc, Marlene ^a   Ting, P T ^b   Man, J ^a   Sawyer, D ^c   Fiorillo, L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Red Deer Regional Hospital Centre   (Canada)

Author keywords

Cytokines; Imiquimod; Localized Scleroderma; Morphoea

Indexed keywords

GAMMA INTERFERON; IMIQUIMOD; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MORPHEA; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN INDURATION; SKIN PIGMENTATION; SKINFOLD THICKNESS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; CHILD; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON INDUCERS; MALE; MIDDLE AGED; SCLERODERMA, LOCALIZED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 26244445840     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06776.x     Document Type: Article

References (18)

1. Sehgal VN, Srivastava G, Aggarwal AK et al. Localized scleroderma/morphea. Int J Dermatol 2002; 41:467-75.
2. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 138:99-105.
3. Jablonska S, Blaszczyk M. Scleroderma and sclerotic skin conditions: unapproved treatments. Clin Dermatol 2002; 20:634-7.
4. Man J, Dytoc MT. Use of imiquimod cream 5% in the treatment of localized morphea. J Cutan Med Surg 2004; 8:166-9.
5. Sambo P, Baroni SS, Luchetti M et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44:2653-64.
6. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14:681-5.
7. Peterson LS, Nelson AM, Su WP et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997; 24:73-80.
8. Yamamoto T. Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma? Clin Immunol 2002; 102:209-16.
9. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286-92.
10. Igarashi A, Nashiro K, Kikuchi K et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996; 106:729-33.
11. Igarashi A, Nashiro K, Kikuchi K et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105:280-4.
12. Sato S, Nagaoka T, Hasegawa M et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27:149-54.
13. Simms RW, Korn JH. Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol 2002; 14:717-22.
14. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984; 74:1112-16.
15. Kahari VM, Heino J, Vuorio T et al. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochim Biophys Acta 1988; 968:45-50.
16. Berman B, Duncan MR. Inhibition of dermal fibrosis by interferons. In: Dermal Immune System (Nickoloff BJ, ed.). Ann Arbor: CRC Press, Inc. 1993; 209-26.
17. Gillery P, Serpier H, Polette M et al. Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. Eur J Cell Biol 1992; 57:244-53.
18. Wagner TL, Ahonen CL, Couture AM et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191:10-19.